Cidara Therapeutics Inc (CDTX)
13.00
0.00 (0.00%)
USD |
NASDAQ |
Apr 26, 16:00
12.70
-0.30
(-2.31%)
After-Hours: 20:00
Cidara Therapeutics Gross Profit Margin (Quarterly): 93.54% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 93.54% |
Date | Value |
---|---|
September 30, 2023 | 96.96% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
93.54%
Minimum
Dec 2023
96.96%
Maximum
Sep 2023
95.25%
Average
95.25%
Median
Gross Profit Margin (Quarterly) Benchmarks
Johnson & Johnson | 69.55% |
NovaBay Pharmaceuticals Inc | 48.70% |
Palatin Technologies Inc | 95.20% |
iBio Inc | -- |
Theriva Biologics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | -414.8% |
Return on Assets | -34.99% |
Return on Invested Capital | -414.8% |
Profit Margin (Quarterly) | -31.91% |
Operating Margin (Quarterly) | -34.54% |
Return on Net Operating Assets | -136.8% |